Document is current
Any future updates will be listed below
-
Authors
Keeley, Tom
Gaw, Nina
Ahmed, Waseem
Alfonso-Cristancho, Rafael
Sousa, Ana R.
Forde, Katie
Sharp, Rosie
Whyman, Sophie
Gater, Adam
-
Funding
Funding for this research was provided by:
GSK (218108)
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 9 December 2024
First Online: 20 December 2024
Declarations
:
: The study was conducted according to the principles outlined in the Declaration of Helsinki, and according to guidelines published by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Additionally, all data was handled in accordance with the European General Data Protection Regulation (GDPR), and data from China was handled in accordance with the PIPL and Data Security Law (DSL). Ethical approval was obtained from Salus Institutional Review Board (IRB), a centralized IRB that provides ethical oversight to research conducted globally for multi-country studies, prior to the collection or processing of participant data (Salus IRB: C218108 GK9381A). Each participant provided written and verbal consent via the informed consent form before their interview was conducted.
: Not applicable.
: TK, NG, WA, RA-C and ARS are employed by GSK and hold financial equities in GSK; KF, RS, SW and AG are employees of Adelphi Values, a consulting company that received funds from GSK to conduct this study but did not receive payment for manuscript development.
